Interferon (IFN)-α has been widely used in systemic therapy for advanced renal cell carcinoma (RCC). IFN-α is represented by a large family of structurally related genes expressing at least 14 subtypes, each of which shows quantitatively distinct patterns of biological activities. Although those distinct patterns of biological activities of IFN-α subtypes against renal cancer cell lines have been demonstrated, there is no report that demonstrates the difference in each subtype-induced antitumor activity in patients with RCC. Herein, we present a unique case of advanced RCC that is resistant to interleukin-2 and IFN-α administration, and we describe its response to another IFN-α administration. The difference between the two IFN-α types lies in the distribution of the subtypes: this case, therefore, suggests that the difference in the subtype distribution may cause the different response of the RCC.
A 47 year-old male was diagnosed as left RCC with multiple lung metastases and underwent radical nephrectomy. The histological diagnosis was pT3b G2 clear cell carcinoma. He received intramuscular administration of 6×10
6 units of natural human IFN-α (Sumiferon
®) three times a week following the operation. However, the lung metastases showed progression. Thereafter, he received intravenous administration of 1.4×10
6 units of human interleukin-2 everyday. However, the lung metastases showed further progression and the hemoptysis, dyspnea, and chest pain deteriorated. Finally, he was given intramuscular administration of 5×10
6 units of another natural human IFN-α (OIF
®) three times a week. After the OIF
® administration, his complaints subsided and a chest CT scan revealed reduced lung metastases and diminished pleural effusion. He had not received any anti-tumor agents other than IFN-α or interleukin-2 since the operation. However, although he remained free of hemoptysis, dyspnea, and chest pain after OIF
® administration, the lung metastases increased again and multiple brain metastases were also observed five months after the first OIF
® administration. He died of metastatic RCC one year after the operation.
View full abstract